Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & Kaya (OTCMKTS:KAYS)

Sarepta Therapeutics (NASDAQ:SRPT) and Kaya (OTCMKTS:KAYS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares Sarepta Therapeutics and Kaya”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$1.50 billion	7.98	-$535.98 million	$0.45	280.00
Kaya	$200,000.00	3.91	$1.61 million	$0.02	1.77

Kaya has lower revenue, but higher earnings than Sarepta Therapeutics. Kaya is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.7% of Sarepta Therapeutics shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 23.5% of Kaya shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sarepta Therapeutics and Kaya’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	3.14%	5.32%	1.50%
Kaya	260.23%	-9.79%	652.87%

Risk and Volatility

Sarepta Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Sarepta Therapeutics and Kaya, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	0	2	18	1	2.95
Kaya	0	0	0	0	N/A

Sarepta Therapeutics presently has a consensus target price of $182.95, indicating a potential upside of 45.20%. Given Sarepta Therapeutics’ higher probable upside, research analysts plainly believe Sarepta Therapeutics is more favorable than Kaya.

Summary

Sarepta Therapeutics beats Kaya on 10 of the 14 factors compared between the two stocks.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.